Curis (CRIS) Competitors $2.77 -0.03 (-1.07%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. IRWD, DOMH, FBIO, SABS, MTEM, AMGN, GILD, VRTX, REGN, and ALNYShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Ironwood Pharmaceuticals (IRWD), Dominari (DOMH), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Ironwood Pharmaceuticals Dominari Fortress Biotech SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Is IRWD or CRIS more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to Curis' net margin of -443.35%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-0.65% -0.96% 0.74% Curis -443.35%-923.37%-78.35% Do insiders & institutionals believe in IRWD or CRIS? 30.0% of Curis shares are held by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer IRWD or CRIS? In the previous week, Curis had 4 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Curis and 1 mentions for Ironwood Pharmaceuticals. Curis' average media sentiment score of 1.09 beat Ironwood Pharmaceuticals' score of 0.43 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Ironwood Pharmaceuticals Neutral Curis Positive Does the MarketBeat Community favor IRWD or CRIS? Curis received 180 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 67.28% of users gave Curis an outperform vote while only 60.73% of users gave Ironwood Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIronwood PharmaceuticalsOutperform Votes51560.73% Underperform Votes33339.27% CurisOutperform Votes69567.28% Underperform Votes33832.72% Do analysts recommend IRWD or CRIS? Ironwood Pharmaceuticals presently has a consensus target price of $4.78, indicating a potential upside of 615.64%. Curis has a consensus target price of $17.00, indicating a potential upside of 513.72%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Curis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, IRWD or CRIS? Curis has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$317.68M0.34-$1.00B-$0.20-3.34Curis$11.20M2.59-$47.41M-$6.23-0.44 Which has more volatility & risk, IRWD or CRIS? Ironwood Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.69, indicating that its share price is 269% more volatile than the S&P 500. SummaryCuris beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.98M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.3532.9027.2119.96Price / Sales2.59466.20408.49157.63Price / CashN/A168.6838.2534.64Price / Book0.833.427.074.69Net Income-$47.41M-$72.35M$3.23B$248.14M7 Day Performance16.88%2.59%0.68%0.91%1 Month Performance30.66%20.47%9.59%5.71%1 Year Performance-67.41%-17.11%32.02%14.71% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.8172 of 5 stars$2.77-1.1%$17.00+513.7%-68.5%$28.98M$11.20M-0.3560News CoveragePositive NewsAnalyst RevisionGap UpIRWDIronwood Pharmaceuticals4.5341 of 5 stars$0.59-3.7%$4.78+716.1%-89.5%$94.84M$317.68M-19.54220Gap UpDOMHDominari1.6177 of 5 stars$5.27-2.4%N/A+144.7%$77.17M$24.89M-1.364Positive NewsFBIOFortress Biotech2.6418 of 5 stars$2.13+6.5%$21.00+885.9%-1.5%$62.98M$57.78M-0.70170SABSSAB Biotherapeutics3.7894 of 5 stars$1.86+2.8%$13.25+612.4%-44.2%$17.28M$2.24M-0.50140Short Interest ↓Gap UpMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.4732 of 5 stars$289.98-0.1%$309.22+6.6%-1.3%$155.92B$34.13B38.4125,200Positive NewsAnalyst RevisionGILDGilead Sciences4.8775 of 5 stars$113.00+0.5%$110.55-2.2%+74.2%$140.56B$28.74B305.4117,000Trending NewsOptions VolumeAnalyst RevisionVRTXVertex Pharmaceuticals4.6549 of 5 stars$446.15-1.0%$515.04+15.4%-3.3%$114.57B$11.10B-202.804,800Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.9034 of 5 stars$517.60+4.9%$836.48+61.6%-49.2%$55.88B$14.09B13.5211,900Analyst RevisionHigh Trading VolumeALNYAlnylam Pharmaceuticals4.2848 of 5 stars$304.00+1.1%$319.17+5.0%+91.6%$39.64B$2.35B-140.092,000Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Ironwood Pharmaceuticals Competitors Dominari Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
